Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update

Eric Van Cutsem, Pieter-Jan Cuyle, Sanne Huijberts, Rona Yaeger, Jan HM Schellens, Elena Elez, Josep Tabernero, Marwan Fakih, Clara Montagut, Marc Peeters, Jayesh Desai, Takayuki Yoshino, Fortunato Ciardiello, Harpreet Singh Wasan, Scott Kopetz, Kati Maharry, Janna Christy-Bittel, Ashwin Gollerkeri, Axel Grothey, None, BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers. Journal of Clinical Oncology. ,vol. 36, pp. 627- 627 ,(2018) , 10.1200/JCO.2018.36.4_SUPPL.627

S. Siena, A. Sartore-Bianchi, S. Marsoni, H.I. Hurwitz, S.J. McCall, F. Penault-Llorca, S. Srock, A. Bardelli, L. Trusolino, Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology. ,vol. 29, pp. 1108- 1119 ,(2018) , 10.1093/ANNONC/MDY100

Jonathan M Loree, Ann M Bailey, Amber M Johnson, Yao Yu, Wenhui Wu, Christopher A Bristow, Jennifer S Davis, Kenna R Shaw, Russell Broaddus, Kimberly C Banks, Richard B Lanman, Funda Meric-Bernstam, Michael J Overman, Scott Kopetz, Kanwal Raghav, Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. Journal of the National Cancer Institute. ,vol. 110, pp. 1409- 1417 ,(2018) , 10.1093/JNCI/DJY067

Jennifer Ma, Jeremy Setton, Nancy Y. Lee, Nadeem Riaz, Simon N. Powell, The therapeutic significance of mutational signatures from DNA repair deficiency in cancer Nature Communications. ,vol. 9, pp. 3292- ,(2018) , 10.1038/S41467-018-05228-Y

Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J. Lin, Viola W. Zhu, Myung-Ju Ahn, D. Ross Camidge, Judy Nguyen, Dayong Zhai, Wei Deng, Zhongdong Huang, Evan Rogers, Juliet Liu, Jeff Whitten, John K. Lim, Shanna Stopatschinskaja, David M. Hyman, Robert C. Doebele, J. Jean Cui, Alice T. Shaw, Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations Cancer Discovery. ,vol. 8, pp. 1227- 1236 ,(2018) , 10.1158/2159-8290.CD-18-0484

Zoran Gatalica, Joanne Xiu, Jeffrey Swensen, Semir Vranic, Molecular characterization of cancers with NTRK gene fusions. Modern Pathology. ,vol. 32, pp. 147- 153 ,(2019) , 10.1038/S41379-018-0118-3

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal, None, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: A Cancer Journal for Clinicians. ,vol. 68, pp. 394- 424 ,(2018) , 10.3322/CAAC.21492

Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Jan Willem B de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D Pickard, Victor Sandor, Caroline Robert, Keith T Flaherty, Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial Lancet Oncology. ,vol. 19, pp. 1315- 1327 ,(2018) , 10.1016/S1470-2045(18)30497-2

Emiliano Cocco, Jamal Benhamida, Sumit Middha, Ahmet Zehir, Kerry Mullaney, Jinru Shia, Rona Yaeger, Liying Zhang, Donna Wong, Liliana Villafania, Khedoudja Nafa, Maurizio Scaltriti, Alexander Drilon, Leonard Saltz, Alison M. Schram, Zsofia K. Stadler, David M. Hyman, Ryma Benayed, Marc Ladanyi, Jaclyn F. Hechtman, Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions Cancer Research. ,vol. 79, pp. 1047- 1053 ,(2019) , 10.1158/0008-5472.CAN-18-3126

Leigh Marcus, Steven J. Lemery, Patricia Keegan, Richard Pazdur, FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors Clinical Cancer Research. ,vol. 25, pp. 3753- 3758 ,(2019) , 10.1158/1078-0432.CCR-18-4070